Royce & Associates LP Makes New Investment in ARS Pharmaceuticals, Inc. $SPRY

Royce & Associates LP bought a new position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm bought 207,051 shares of the company’s stock, valued at approximately $2,412,000.

Other institutional investors have also bought and sold shares of the company. Bamco Inc. NY lifted its stake in ARS Pharmaceuticals by 3,071.3% in the 3rd quarter. Bamco Inc. NY now owns 1,268,532 shares of the company’s stock worth $12,749,000 after purchasing an additional 1,228,532 shares in the last quarter. Casdin Capital LLC acquired a new stake in shares of ARS Pharmaceuticals during the 3rd quarter worth approximately $16,080,000. American Assets Inc. acquired a new stake in shares of ARS Pharmaceuticals during the 3rd quarter worth approximately $553,000. Levin Capital Strategies L.P. increased its holdings in shares of ARS Pharmaceuticals by 157.6% during the 3rd quarter. Levin Capital Strategies L.P. now owns 764,294 shares of the company’s stock worth $7,681,000 after buying an additional 467,647 shares during the last quarter. Finally, Aberdeen Group plc increased its holdings in shares of ARS Pharmaceuticals by 106.1% during the 3rd quarter. Aberdeen Group plc now owns 3,097,022 shares of the company’s stock worth $31,125,000 after buying an additional 1,594,447 shares during the last quarter. 68.16% of the stock is owned by hedge funds and other institutional investors.

ARS Pharmaceuticals Stock Down 3.5%

Shares of NASDAQ SPRY opened at $9.07 on Friday. The company has a 50 day simple moving average of $8.19 and a 200-day simple moving average of $9.24. The company has a market capitalization of $900.65 million, a P/E ratio of -4.51 and a beta of 0.93. The company has a debt-to-equity ratio of 2.79, a current ratio of 4.94 and a quick ratio of 4.77. ARS Pharmaceuticals, Inc. has a 1 year low of $6.66 and a 1 year high of $18.90.

ARS Pharmaceuticals (NASDAQ:SPRY) last posted its earnings results on Friday, May 15th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.08). ARS Pharmaceuticals had a negative net margin of 200.00% and a negative return on equity of 153.61%. The company had revenue of $22.68 million during the quarter, compared to analyst estimates of $22.20 million. On average, equities research analysts predict that ARS Pharmaceuticals, Inc. will post -1.75 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on SPRY shares. Northland Securities started coverage on shares of ARS Pharmaceuticals in a report on Thursday, April 9th. They set an “outperform” rating and a $25.00 price target for the company. Leerink Partners set a $26.00 price target on shares of ARS Pharmaceuticals and gave the stock an “outperform” rating in a report on Tuesday, March 10th. Cantor Fitzgerald raised their price target on shares of ARS Pharmaceuticals from $12.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday. Wall Street Zen upgraded shares of ARS Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Finally, Weiss Ratings downgraded shares of ARS Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 15th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $28.60.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.